Novoneuron Inc. v. Addiction Research Institute, Inc.

326 F. App'x 505
CourtCourt of Appeals for the Eleventh Circuit
DecidedApril 28, 2009
Docket08-12028
StatusUnpublished
Cited by6 cases

This text of 326 F. App'x 505 (Novoneuron Inc. v. Addiction Research Institute, Inc.) is published on Counsel Stack Legal Research, covering Court of Appeals for the Eleventh Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Novoneuron Inc. v. Addiction Research Institute, Inc., 326 F. App'x 505 (11th Cir. 2009).

Opinion

PER CURIAM:

I. Facts and Procedural History

This case arises out of a patent dispute between Plaintiff-Appellant Novoneuron, Inc. (“Novoneuron”) and Defendanb-Ap-pellees Addiction Research Institute, Inc. and Robert Rand (collectively “Appel-lees”), concerning the rights to certain intellectual properties. In 2000, the parties entered a settlement agreement (“the Agreement”), wherein Appellees assigned to Novoneuron “all right, title, and interest” in intellectual properties embodied in U.S. Patent Number 5,591,738 (“the Patent”) and U.S. Patent Application Number 08/280,187 (“the Application”). 1

In 2007, Novoneuron filed the instant suit, alleging that Appellees breached the Agreement by attempting to patent those same intellectual properties in a variety of foreign countries, and sought damages and injunctive relief. Shortly thereafter, Ap-pellees filed a motion to dismiss under Fed. R. Civ. P. (“Rule”) 12(b)(6) for failure to state claim upon which relief could be granted. Novoneuron sought and was granted leave to amend the complaint. After Novoneuron amended the complaint, Appellees again filed a Rule 12(b)(6) motion, arguing that Novoneuron had failed to state a claim because the Agreement only assigns U.S. patent rights. It argued that because the Agreement is limited to the U.S. patent rights, Novoneuron could not prevail on its claim that the Appellees breached the Agreement by applying for patents in foreign countries. Novoneuron did not seek leave to further amend the complaint, but rather opposed the motion to dismiss, arguing, inter alia, that the Agreement assigns worldwide rights to the intelleetual properties described in the Patent and the Application.

The district court issued an order concluding that the Agreement is limited to U.S. patent rights and therefore dismissed the action with prejudice for failure to state a claim. On appeal, Novoneuron argues that the district court abused its discretion by dismissing the complaint with prejudice, rather than sua sponte permitting Novoneuron to seek leave to further amend the complaint. It argues that if permitted to amend, it could have pursued a theory of unilateral mistake. Alternatively, Novoneuron argues that the district court erred in finding the Agreement unambiguous on its face.

II. Discussion

A. Standard of Review

We review the grant of a motion to dismiss under Rule 12(b)(6) for failure to state a claim de novo, accepting the allegations in the complaint as true and construing them in the light most favorable to the plaintiff. Glover v. Liggett Group, Inc., 459 F.3d 1304, 1308 (11th Cir.2006). We also review de novo the issue of whether a contract is ambiguous. Fraila v. CRA Holdings, Inc., 543 F.3d 1247, 1252 (11th Cir.2008).

B. Opportunity to Amend

Novoneuron argues that the district court “rushed to judgment” by dismissing the complaint with prejudice after only one amendment. Novoneuron concedes that it did not request leave to further amend, but nonetheless argues that instead the district court should have sua sponte invited Novoneuron to seek leave to further amend the complaint.

*507 Rule 15 permits a party one amendment as a matter of right before being served with a responsive pleading. Fed.R.Civ.P. 15(a)(1). 2 Once a party has used its one free amendment or a responsive pleading has been filed, however, it may only amend with the other party’s written consent or by leave of the court. Id. at 15(a)(2). In Wagner v. Daewoo Heavy Indus. America Corp., 314 F.3d 541 (11th Cir.2002) (en banc), this court held that a “district court is not required to grant a plaintiff leave to amend his complaint sua sponte when the plaintiff, who is represented by counsel, never filed a motion to amend nor requested leave to amend before the district court.” Id. at 542.

We conclude that Wagner controls the outcome of the instant case. Novoneuron had the benefit of counsel, but did not request leave to further amend its complaint. Instead, it filed a response to the Appellees’ motion to dismiss. The district court was not obligated to sua sponte grant Novoneuron leave to amend, and therefore Novoneuron’s argument fails.

C. Unilateral Mistake

Novoneuron argues that had it been permitted to amend, it could have pursued a theory of unilateral mistake. The doctrine of unilateral mistake is available in cases where the plaintiff seeks equitable rescission of the contract. See Roberts & Schaefer Co. v. Hardaway Co., 152 F.3d 1283, 1295 (11th Cir.1998); Maryland Cas. Co. v. Krasnek, 174 So.2d 541, 543 (Fla.1965). 3 Because Novoneuron was not entitled to amend its complaint to pursue such a theory, see supra, we conclude that Novoneuron’s unilateral mistake argument necessarily fails. 4

D. Ambiguity

Finally, Novoneuron argues that the district court erred in finding the Agreement unambiguous. 5 Section 2.1 of the Agree *508 ment assigns “all right, title, and interest in the patent and patent application known as U.S. Patent Number 5,591,738 (‘Method of Treating Chemical Dependency Using Betacarboline Alkaloids Derivatives and Salts Thereof) and U.S. Patent Application Serial Number 08/280,187, including any claimed interest in these intellectual properties” to Novoneuron. Novoneuron argues that this section should be read to grant worldwide property rights in the subject matter of the Patent and Application, whereas Appellees argue that the Agreement is limited to assignment of U.S. patent rights.

“[T]he ‘accepted rule’ for appraising the sufficiency of a complaint is ‘that a complaint should not be dismissed for failure to state a claim unless it appears beyond doubt that the plaintiff can prove no set of facts in support of his claim which would entitle him to relief.’ ” S.E.C. v. ESM Group, Inc., 835 F.2d 270, 272 (11th Cir.1988) (quoting Conley v. Gibson, 355 U.S. 41, 45-46, 78 S.Ct. 99, 2 L.Ed.2d 80 (1957)).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Pearson v. Deutsche Bank AG
S.D. Florida, 2022
Wistar v. Raymond James Fin. Servs., Inc.
365 F. Supp. 3d 1266 (S.D. Florida, 2018)
Brink v. Raymond James & Assocs., Inc.
341 F. Supp. 3d 1314 (S.D. Florida, 2018)
Bank of America, N. A. v. Federal Deposit Insurance
908 F. Supp. 2d 60 (D.C. Circuit, 2012)
In Re Fontainebleau Las Vegas Contract Litigation
716 F. Supp. 2d 1237 (S.D. Florida, 2010)

Cite This Page — Counsel Stack

Bluebook (online)
326 F. App'x 505, Counsel Stack Legal Research, https://law.counselstack.com/opinion/novoneuron-inc-v-addiction-research-institute-inc-ca11-2009.